Alpha 1 Lung Disease Market Size, Share & Trends Analysis Report By Disease Type (Alpha-1 Antitrypsin Deficiency, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Fibrosis, Bronchiectasis, Others), By Treatment Type (Augmentation Therapy, Bronchodilators, Corticosteroids, Oxygen Therapy, Lung Transplantation, Others), By Route of Administration, By Distribution Channel, By End User, By Region, And By Segment Forecasts, 2023-2031.

Report Id: 2274 Pages: 180 Last Updated: 16 March 2024 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

Segmentation of Alpha 1 Lung Disease Market-

Alpha 1 Lung Disease Market By Disease Type-

  • Alpha-1 Antitrypsin Deficiency
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Pulmonary Fibrosis
  • Bronchiectasis
  • Others

Alpha 1 Lung Disease Market Seg

Alpha 1 Lung Disease Market By Treatment Type-

  • Augmentation Therapy
  • Bronchodilators
  • Corticosteroids
  • Oxygen Therapy
  • Lung Transplantation
  • Others

Alpha 1 Lung Disease Market By Route of Administration-

  • Inhalation
  • Injectable
  • Oral

Alpha 1 Lung Disease Market By Distribution Channel-

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Alpha 1 Lung Disease Market By End User-

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Alpha 1 Lung Disease Market By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Alpha 1 Lung Disease Market Snapshot

Chapter 4. Global Alpha 1 Lung Disease Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: By Disease Type Estimates & Trend Analysis

5.1. By Disease Type, & Market Share, 2019 & 2031

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 for the following By Disease Type:

5.2.1. Alpha-1 Antitrypsin Deficiency

5.2.2. Chronic Obstructive Pulmonary Disease (COPD)

5.2.3. Pulmonary Fibrosis

5.2.4. Bronchiectasis

5.2.5. Others

Chapter 6. Market Segmentation 2: By Treatment Type Estimates & Trend Analysis

6.1. By Treatment Type & Market Share, 2019 & 2031

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 for the following By Treatment Type:

6.2.1. Augmentation Therapy

6.2.2. Bronchodilators

6.2.3. Corticosteroids

6.2.4. Oxygen Therapy

6.2.5. Lung Transplantation

6.2.6. Others

Chapter 7. Market Segmentation 3: By Route of Administration Estimates & Trend Analysis

7.1. By Route of Administration & Market Share, 2019 & 2031

7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 for the following By Route of Administration:

7.2.1. Inhalation

7.2.2. Injectable

7.2.3. Oral

Chapter 8. Market Segmentation 4: By Distribution Channel Estimates & Trend Analysis

8.1. By Distribution Channel & Market Share, 2019 & 2031

8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 for the following By Distribution Channel:

8.2.1. Hospital Pharmacies

8.2.2. Retail Pharmacies

8.2.3. Online Pharmacies

Chapter 9. Market Segmentation 5: By End-Users Estimates & Trend Analysis

9.1. By End-Users & Market Share, 2019 & 2031

9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 for the following By End-Users:

9.2.1. Hospitals

9.2.2. Homecare

9.2.3. Specialty Clinics

9.2.4. Others

Chapter 10. Alpha 1 Lung Disease Market Segmentation 6: Regional Estimates & Trend Analysis

10.1. North America

10.1.1. North America Alpha 1 Lung Disease Market revenue (US$ Million) estimates and forecasts By Disease Type, 2023-2031

10.1.2. North America Alpha 1 Lung Disease Market revenue (US$ Million) estimates and forecasts By Treatment Type, 2023-2031

10.1.3. North America Alpha 1 Lung Disease Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2023-2031

10.1.4. North America Alpha 1 Lung Disease Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2023-2031

10.1.5. North America Alpha 1 Lung Disease Market revenue (US$ Million) estimates and forecasts By End-Users, 2023-2031

10.1.6. North America Alpha 1 Lung Disease Market revenue (US$ Million) estimates and forecasts by country, 2023-2031

10.2. Europe

10.2.1. Europe Alpha 1 Lung Disease Market revenue (US$ Million) By Disease Type, 2023-2031

10.2.2. Europe Alpha 1 Lung Disease Market revenue (US$ Million) By Treatment Type, 2023-2031

10.2.3. Europe Alpha 1 Lung Disease Market revenue (US$ Million) By Route of Administration, 2023-2031

10.2.4. Europe Alpha 1 Lung Disease Market revenue (US$ Million) By Distribution Channel, 2023-2031

10.2.5. Europe Alpha 1 Lung Disease Market revenue (US$ Million) By End-Users, 2023-2031

10.2.6. Europe Alpha 1 Lung Disease Market revenue (US$ Million) by country, 2023-2031

10.3. Asia Pacific

10.3.1. Asia Pacific Alpha 1 Lung Disease Market revenue (US$ Million) By Disease Type, 2023-2031

10.3.2. Asia Pacific Alpha 1 Lung Disease Market revenue (US$ Million) By Treatment Type, 2023-2031

10.3.3. Asia Pacific Alpha 1 Lung Disease Market revenue (US$ Million) By Route of Administration, 2023-2031

10.3.4. Asia Pacific Alpha 1 Lung Disease Market revenue (US$ Million) By Distribution Channel, 2023-2031

10.3.5. Asia Pacific Alpha 1 Lung Disease Market revenue (US$ Million) By End-Users, 2023-2031

10.3.6. Asia Pacific Alpha 1 Lung Disease Market revenue (US$ Million) by country, 2023-2031

10.4. Latin America

10.4.1. Latin America Alpha 1 Lung Disease Market revenue (US$ Million) By Disease Type, (US$ Million) 2023-2031

10.4.2. Latin America Alpha 1 Lung Disease Market revenue (US$ Million) By Treatment Type, (US$ Million) 2023-2031

10.4.3. Latin America Alpha 1 Lung Disease Market revenue (US$ Million) By Route of Administration, (US$ Million) 2023-2031

10.4.4. Latin America Alpha 1 Lung Disease Market revenue (US$ Million) By Distribution Channel, (US$ Million) 2023-2031

10.4.5. Latin America Alpha 1 Lung Disease Market revenue (US$ Million) By End-Users, (US$ Million) 2023-2031

10.4.6. Latin America Alpha 1 Lung Disease Market revenue (US$ Million) by country, 2023-2031

10.5. Middle East & Africa

10.5.1. Middle East & Africa Alpha 1 Lung Disease Market revenue (US$ Million) By Disease Type, (US$ Million) 2023-2031

10.5.2. Middle East & Africa Alpha 1 Lung Disease Market revenue (US$ Million) By Treatment Type, (US$ Million) 2023-2031

10.5.3. Middle East & Africa Alpha 1 Lung Disease Market revenue (US$ Million) By Route of Administration, (US$ Million) 2023-2031

10.5.4. Middle East & Africa Alpha 1 Lung Disease Market revenue (US$ Million) By Distribution Channel, (US$ Million) 2023-2031

10.5.5. Middle East & Africa Alpha 1 Lung Disease Market revenue (US$ Million) By End-Users, (US$ Million) 2023-2031

10.5.6. Middle East & Africa Alpha 1 Lung Disease Market revenue (US$ Million) by country, 2023-2031

Chapter 11. Competitive Landscape

11.1. Major Mergers and Acquisitions/Strategic Alliances

11.2. Company Profiles

11.2.1. AstraZeneca,

11.2.2. Boehringer Ingelheim,

11.2.3. Roche ,

11.2.4. Novartis,

11.2.5. Pfizer,

11.2.6. Merck,

11.2.7. Bristol-Myers Squibb,

11.2.8. Takeda Pharmaceutical,

11.2.9. CSL Behring,

11.2.10. Vertex Pharmaceuticals,

11.2.11. Amgen,

11.2.12. Sanofi,

11.2.13. GlaxoSmithKline,

11.2.14. Gilead Sciences ,

11.2.15. Eli Lilly,

11.2.16. AbbVie,

11.2.17. Johnson & Johnson,

11.2.18. Teva Pharmaceutical,

11.2.19. Audentes Therapeutics,

11.2.20. Regeneron Pharmaceuticals

11.2.21. LFB Biomedicaments

11.2.22. Grifols

11.2.23. Kamada Ltd

11.2.24. Others

Research Design and Approach

This study employed a multi-step, mixed-method research approach that integrates:

  • Secondary research
  • Primary research
  • Data triangulation
  • Hybrid top-down and bottom-up modelling
  • Forecasting and scenario analysis

This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.

Secondary Research

Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.

Sources Consulted

Secondary data for the market study was gathered from multiple credible sources, including:

  • Government databases, regulatory bodies, and public institutions
  • International organizations (WHO, OECD, IMF, World Bank, etc.)
  • Commercial and paid databases
  • Industry associations, trade publications, and technical journals
  • Company annual reports, investor presentations, press releases, and SEC filings
  • Academic research papers, patents, and scientific literature
  • Previous market research publications and syndicated reports

These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.

Secondary Research

Primary Research

Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.

Stakeholders Interviewed

Primary interviews for this study involved:

  • Manufacturers and suppliers in the market value chain
  • Distributors, channel partners, and integrators
  • End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
  • Industry experts, technology specialists, consultants, and regulatory professionals
  • Senior executives (CEOs, CTOs, VPs, Directors) and product managers

Interview Process

Interviews were conducted via:

  • Structured and semi-structured questionnaires
  • Telephonic and video interactions
  • Email correspondences
  • Expert consultation sessions

Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.

Data Processing, Normalization, and Validation

All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.

The data validation process included:

  • Standardization of units (currency conversions, volume units, inflation adjustments)
  • Cross-verification of data points across multiple secondary sources
  • Normalization of inconsistent datasets
  • Identification and resolution of data gaps
  • Outlier detection and removal through algorithmic and manual checks
  • Plausibility and coherence checks across segments and geographies

This ensured that the dataset used for modelling was clean, robust, and reliable.

Market Size Estimation and Data Triangulation

Bottom-Up Approach

The bottom-up approach involved aggregating segment-level data, such as:

  • Company revenues
  • Product-level sales
  • Installed base/usage volumes
  • Adoption and penetration rates
  • Pricing analysis

This method was primarily used when detailed micro-level market data were available.

Bottom Up Approach

Top-Down Approach

The top-down approach used macro-level indicators:

  • Parent market benchmarks
  • Global/regional industry trends
  • Economic indicators (GDP, demographics, spending patterns)
  • Penetration and usage ratios

This approach was used for segments where granular data were limited or inconsistent.

Hybrid Triangulation Approach

To ensure accuracy, a triangulated hybrid model was used. This included:

  • Reconciling top-down and bottom-up estimates
  • Cross-checking revenues, volumes, and pricing assumptions
  • Incorporating expert insights to validate segment splits and adoption rates

This multi-angle validation yielded the final market size.

Forecasting Framework and Scenario Modelling

Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.

Forecasting Methods

  • Time-series modelling
  • S-curve and diffusion models (for emerging technologies)
  • Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
  • Price elasticity models
  • Market maturity and lifecycle-based projections

Scenario Analysis

Given inherent uncertainties, three scenarios were constructed:

  • Base-Case Scenario: Expected trajectory under current conditions
  • Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
  • Conservative Scenario: Slow adoption, regulatory delays, economic constraints

Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.

Name field cannot be blank!
Email field cannot be blank!(Use email format)
Designation field cannot be blank!
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
1869
Security Code field cannot be blank!

Frequently Asked Questions

Alpha 1 Lung Disease Market Size is valued at USD 4.13 Billion in 2022 and is predicted to reach USD 19.93 Billion by the year 2031

Alpha 1 Lung Disease Market expected to grow at a 19.33% CAGR during the forecast period for 2023-2031.

Teva Pharmaceutical, Audentes Therapeutics, Regeneron Pharmaceuticals, LFB Biomedicaments, Grifols, Kamada Ltd, and Others

Report License Selection

Determine the Appropriate License for your Report

Get Sample Report Enquiry Before Buying